Compare NUVL & SOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | SOLS |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.9B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | SOLS |
|---|---|---|
| Price | $105.96 | $61.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 3 |
| Target Price | ★ $135.00 | $55.00 |
| AVG Volume (30 Days) | 548.0K | ★ 4.1M |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $3,812,000,000.00 |
| Revenue This Year | N/A | $3.34 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ N/A | $29.38 |
| Revenue Growth | N/A | ★ 4.47 |
| 52 Week Low | $55.54 | $40.43 |
| 52 Week High | $112.88 | $61.60 |
| Indicator | NUVL | SOLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | N/A |
| Support Level | $97.43 | N/A |
| Resistance Level | $108.65 | N/A |
| Average True Range (ATR) | 4.63 | 0.00 |
| MACD | 0.48 | 0.00 |
| Stochastic Oscillator | 79.92 | 0.00 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.